Literature DB >> 10541947

Phototherapy for neonatal hyperbilirubinemia affects cytokine production by peripheral blood mononuclear cells.

L Sirota1, R Straussberg, N Gurary, D Aloni, H Bessler.   

Abstract

The capacity of peripheral blood mononuclear cells (PBMC) to produce interleukin (IL) IL-1beta, IL-2, IL-3, IL-6, IL-10 and tumor necrosis factor-alpha (TNFalpha) was examined in term newborns with hyperbilirubinemia after 24 hours' exposure to phototherapy (wave length 425-475 nm). The results were compared with those from untreated neonates. Fifty newborns spontaneously delivered at term were included in the study. Blood samples were collected from 20 newborns before and 24 h after phototherapy. The control group consisted of 30 neonates examined on two consecutive days. PBMC isolated from blood samples were incubated in vitro for cytokine production. The concentration of cytokines in the supernatants was tested using ELISA kits (for IL-1beta, IL-6, IL-10 and TNFalpha), or by bioassays (for IL-2 and IL-3). Phototherapy caused a 70% increase in IL-2 secretion (123 +/- 27 vs 208 +/- 30 units/ml, P < 0.01) and 56% in IL-10 production (1.07 +/- 0.19 vs 1.67 +/- 0.33 ng/ml, P < 0. 03), whereas the spontaneous secretion of IL-1beta was reduced by 43% (13.7 +/- 2.3 vs 7.3 +/- 1.7 ng/ml, P < 0.02). In the control group the secretion of these cytokines was similar on the two consecutive days and did not differ significantly from secretion in the other group before phototherapy. On the other hand, lipopolysaccharide induced TNFalpha production was higher on the second day in the two groups of newborns irrespective of phototherapy (388 +/- 58 vs 683 +/- 88 pg/ml, P < 0.001, in the control group and 384 +/- 75 vs 588 +/- 91, P < 0.05, before and after phototherapy). The synthesis of IL-3 and IL-6 did not change significantly between the two days of the study. The results demonstrate that in addition to the well-known positive effect of phototherapy on the neonate serum bilirubin level, this treatment affects the function of the immune system in newborns via alterations in cytokine production.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10541947     DOI: 10.1007/s004310051240

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  7 in total

1.  Effect of phototherapy on gastrointestinal smooth muscle activity and oxidative stress.

Authors:  Tutku Soyer; Didem Aliefendioğlu; Zuhal Aktuna; Osman Cağlayan; Tolga Reşat Aydos; Murat Cakmak
Journal:  Pediatr Surg Int       Date:  2011-06-01       Impact factor: 1.827

2.  Sister Jean Ward, phototherapy, and jaundice: a unique human and photochemical interaction.

Authors:  M J Maisels
Journal:  J Perinatol       Date:  2015-06-11       Impact factor: 2.521

3.  Double versus single intensive phototherapy with LEDs in treatment of neonatal hyperbilirubinemia.

Authors:  M L Donneborg; P K Vandborg; B M Hansen; M Rodrigo-Domingo; F Ebbesen
Journal:  J Perinatol       Date:  2017-11-02       Impact factor: 2.521

4.  Body temperature changes of newborns under fluorescent versus LED phototherapy.

Authors:  Ozge Aydemir; Emel Soysaldı; Yusuf Kale; Sumru Kavurt; Ahmet Yagmur Bas; Nihal Demirel
Journal:  Indian J Pediatr       Date:  2013-09-14       Impact factor: 1.967

5.  Effects of phototherapy on cytokines' levels and white blood cells in term neonate with hyperbilirubinemia.

Authors:  Sedigheh Jahanshahifard; Mousa Ahmadpour-Kacho; Yadollah Zahed Pasha
Journal:  J Clin Neonatol       Date:  2012-07

6.  Blood eosinophil levels in newborns with severe indirect hyperbilirubinemia treated with phototherapy.

Authors:  Banu Aydın; Serdar Beken; Ayşegül Zenciroğlu; Dilek Dilli; Nurullah Okumuş
Journal:  Iran J Pediatr       Date:  2014-06       Impact factor: 0.364

7.  Risk of autism spectrum disorder in children with a history of hospitalization for neonatal jaundice.

Authors:  Gaffari Tunç; Ayla Uzun Çiçek; Fatih Kiliçbay
Journal:  Turk J Med Sci       Date:  2021-08-04       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.